These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3858583)

  • 1. Design of cancer assays for pharmaceutical agents.
    Meyers DB; Young SS; Gries CL
    J Natl Cancer Inst; 1985 May; 74(5):1151-2. PubMed ID: 3858583
    [No Abstract]   [Full Text] [Related]  

  • 2. Design of cancer assays for pharmaceutical agents: a reply.
    Boorman GA; Huff JE; Schwetz BA
    J Natl Cancer Inst; 1986 Aug; 77(2):589-90. PubMed ID: 3461218
    [No Abstract]   [Full Text] [Related]  

  • 3. [Carcinogenicity studies in experimental animals. II. Interpretation of the results and significance for man].
    Feron VJ; de Vrijer F; van der Heijden CA
    Ned Tijdschr Geneeskd; 1986 Jun; 130(23):1051-4. PubMed ID: 3724898
    [No Abstract]   [Full Text] [Related]  

  • 4. Design of cancer assays for pharmaceutical agents.
    Ciminera JL; Heyse JF; Mantel N; Pitot PC
    J Natl Cancer Inst; 1984 Jun; 72(6):1212. PubMed ID: 6587143
    [No Abstract]   [Full Text] [Related]  

  • 5. Environmental cancer: animal studies and assay procedures.
    Griffin AC
    Tex Rep Biol Med; 1978; 37():45-9. PubMed ID: 752984
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of carcinogenicity studies with aldrin and dieldrin.
    Ritper DL
    J Assoc Off Anal Chem; 1979 Jul; 62(4):900-3. PubMed ID: 500539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of two sequential applications of initiators in the production of hepatomas in the rat: an examination of the Solt-Farber protocol.
    Potter VR
    Cancer Res; 1984 Jun; 44(6):2733-6. PubMed ID: 6722804
    [No Abstract]   [Full Text] [Related]  

  • 8. Considerations in the interpretation of animal bioassays for chemical carcinogenicity.
    Griesemer RA
    Transplant Proc; 1984 Apr; 16(2):412-5. PubMed ID: 6372175
    [No Abstract]   [Full Text] [Related]  

  • 9. Rationale for deployment of short-term assays for evidence of carcinogenicity.
    Drake JW; de Serres FJ; Darby WJ; Dunkel VC; Longfellow DG; Ott H; Purchase IF; Ramel C; Schlatter C; Smith EM
    IARC Monogr Eval Carcinog Risk Chem Hum Suppl; 1980; (2 Suppl):295-308. PubMed ID: 6935184
    [No Abstract]   [Full Text] [Related]  

  • 10. Future possibilities for shorter-term assays of carcinogenicity.
    Sivak A
    Transplant Proc; 1984 Apr; 16(2):403-5. PubMed ID: 6719545
    [No Abstract]   [Full Text] [Related]  

  • 11. Basic requirements for long-term assays for carcinogenicity.
    Feron VJ; Grice HC; Griesemer R; Peto R; Agthe C; Althoff J; Arnold DL; Blumenthal H; Cabral JR; Della Porta G; Ito N; Kimmerle G; Kroes R; Mohr U; Napalkov NP; Odashima S; Page NP; Schramm T; Steinhoff D; Sugar J; Tomatis L; Uehleke H; Vouk V
    IARC Monogr Eval Carcinog Risk Chem Hum Suppl; 1980; (2 Suppl):21-83. PubMed ID: 6935180
    [No Abstract]   [Full Text] [Related]  

  • 12. Cooperative programme on long-term assays for carcinogenicity in Japan.
    Odashima S
    IARC Sci Publ; 1980; (27):315-22. PubMed ID: 7439964
    [No Abstract]   [Full Text] [Related]  

  • 13. [Carcinogenicity studies in experimental animals. I. Design and performance].
    Feron VJ; de Vrijer F; van der Heijden CA
    Ned Tijdschr Geneeskd; 1986 Jun; 130(23):1049-51. PubMed ID: 3724897
    [No Abstract]   [Full Text] [Related]  

  • 14. Prospects of short-term tests in primary cancer prevention.
    Khudoley VV; Pliss GB
    Neoplasma; 1984; 31(4):475-8. PubMed ID: 6472519
    [No Abstract]   [Full Text] [Related]  

  • 15. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.
    Venditti JM
    Cancer Treat Rep; 1983 Sep; 67(9):767-72. PubMed ID: 6883352
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of in-vitro assays to study and to detect tumour promoters.
    Trosko JE; Jone C; Chang CC
    IARC Sci Publ; 1984; (56):239-52. PubMed ID: 6536597
    [No Abstract]   [Full Text] [Related]  

  • 17. Development and utilization of inbred strains of mice for cancer research.
    Heston WE
    Prog Clin Biol Res; 1981; 45():279-90. PubMed ID: 7243819
    [No Abstract]   [Full Text] [Related]  

  • 18. 2nd International symposium of the Society of Toxicologic Pathologists. Design of carcinogenicity studies: considerations in pathology interpretation. May 9-11, 1983, Arlington, Virginia.
    Toxicol Pathol; 1983; 11(1):28-95. PubMed ID: 6681393
    [No Abstract]   [Full Text] [Related]  

  • 19. Validation of tests for carcinogenicity.
    Purchase IF
    IARC Sci Publ; 1980; (27):343-9. PubMed ID: 7002781
    [No Abstract]   [Full Text] [Related]  

  • 20. Limitations of metabolic activation systems used in short-term tests for carcinogens.
    Bigger CA; Dipple A
    Dev Toxicol Environ Sci; 1980; 8():171-4. PubMed ID: 6796372
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.